Scinai Immunotherapeutics Ltd.
SCNI evidence brief
What we can confirm
What it means
What to watch
Prepared research question
What matters most for SCNI—catalysts, financial risk and supporting evidence?
Traceable citations · Unknowns marked
BioSniper AI · SCNI
Scinai Immunotherapeutics Ltd. is a developmental-stage biopharmaceutical company with two complementary business units: an R&D pipeline focused on inflammation and immunology (including a NanoAb platform and the PC111 program) and a contract development and manufacturing organization (CDMO) subsidiary. The company has no approved products, limited cash, and requires substantial additional financing to continue operations.
Key risk: Cash runway insufficient
BioSniper Score
Based on 2 of 6 signals
Limited data coverage
Financial data as of Dec 31, 2025.
Scinai Immunotherapeutics Ltd. is a developmental-stage biopharmaceutical company with two complementary business units: an R&D pipeline focused on inflammation and immunology (including a NanoAb platform and the PC111 program) and a contract development and manufacturing organization (CDMO) subsidiary. The company has no approved products, limited cash, and requires substantial additional financing to continue operations.
- Scinai operates two business units: Scinai R&D (inflammation/immunology therapeutics) and a CDMO subsidiary, Scinai Biopharma Services Ltd. [sec · filed 2026-04-01]
- As of December 31, 2025, the company had cash & equivalents of $1.8M, total revenue of $1.3M, and a net loss of -$8.3M [sec]. Accumulated deficit was $125.8M as of the same date [sec · filed 2026-04-01].
- The R&D pipeline includes the PC111 program (a fully human monoclonal antibody for severe dermatological conditions, acquired via option agreement) and a NanoAbs platform targeting inflammation and immunology [sec · filed 2026-04-01].
- The company has no product candidates in clinical trials or on the market, and its preclinical pipeline remains limited [sec · filed 2026-04-01].
- Existing cash resources are not sufficient to fund projected cash requirements for at least the next 12 months, and significant additional financing will be needed [sec · filed 2026-04-01].
What works
- The company has a diversified strategy combining internal R&D (NanoAbs, PC111) with a revenue-generating CDMO business, which may provide non-dilutive funding and operational synergies [sec · filed 2026-04-01].
- The PC111 program targets a clear biological pathway (keratinocyte cell death and inflammation) with potential applications in severe dermatological conditions, offering a defined development pathway [sec · filed 2026-04-01].
- The NanoAb platform leverages VHH antibody fragments, which may offer advantages in stability, production, and tissue penetration compared to conventional antibodies [sec · filed 2026-04-01].
What to weigh
- The company has no approved products, no product candidates in clinical trials, and a limited preclinical pipeline, indicating high development risk [sec · filed 2026-04-01].
- Cash resources of $1.8M (as of 2025-12-31) are insufficient to fund operations for the next 12 months, and the company will require substantial additional financing, which may cause dilution or force asset relinquishment [sec · filed 2026-04-01].
- The IL-17 program may be modified, delayed, or discontinued, which could result in loss of rights under the applicable license agreement and materially harm the business [sec · filed 2026-04-01].
- The company has an accumulated deficit of $125.8M (as of 2025-12-31) and has never been profitable, with no guarantee of future profitability [sec · filed 2026-04-01].
From the filings
Quoted directly from source documents.
Scinai has two business units: R&D and CDMO.
“We are a biopharmaceutical company with two complementary business units: (i) Scinai R&D, focused on the development of innovative therapeutics in inflammation and immunology, and (ii) our contract development and manufacturing organization (CDMO) business, which operates through our subsidiary, Scinai Biopharma Services Ltd.”
SEC filings · April 1, 2026
Cash is insufficient for 12 months.
“Our existing cash resources are not sufficient to fund our projected cash requirements at current monthly rates for at least the next 12 months, and we will require significant additional financing in the future to fund our operations”
SEC filings · April 1, 2026
No product candidates in clinical trials.
“we currently have no product candidates in clinical trials or on the market, and our preclinical pipeline remains limited.”
SEC filings · April 1, 2026
Accumulated deficit of $125.8M as of 2025-12-31.
“an accumulated deficit of $125.8 million and $117.6 million, respectively.”
SEC filings · April 1, 2026
Risks & what to watch (4)›
Key risks
- Cash runway insufficient — Cash of $1.8M (as of 2025-12-31) is not enough for 12 months; significant additional financing required [sec · filed 2026-04-01].
- No clinical-stage assets — No product candidates in clinical trials; preclinical pipeline is limited, increasing development risk [sec · filed 2026-04-01].
- IL-17 program uncertainty — The IL-17 program may be modified, delayed, or discontinued, risking loss of license rights [sec · filed 2026-04-01].
- History of losses — Accumulated deficit of $125.8M (as of 2025-12-31); no profitability achieved or guaranteed [sec · filed 2026-04-01].
What to watch
- Ability to secure additional financing (equity, debt, partnerships) to extend cash runway beyond 12 months [sec · filed 2026-04-01].
- Progress of the PC111 program (option agreement with Pincell S.r.l.) toward preclinical or clinical milestones [sec · filed 2026-04-01].
- Revenue growth and profitability of the CDMO business (Scinai Biopharma Services Ltd.) as a potential non-dilutive funding source [sec · filed 2026-04-01].
- Any updates on the NanoAb platform, including licensing or partnership opportunities [sec · filed 2026-04-01].
Sources: SEC filings · Generated August 27, 2026 · How we verify sources →
Run Scinai Immunotherapeutics Ltd. through your own thesis
Use the pipeline, catalyst, financial, FDA, and market facts on this page as inputs to a protocol you control.
Your protocol can:
- Turn available Scinai Immunotherapeutics Ltd. facts into screen rules or deeper checks
- Show cited findings, blockers, and unresolved evidence together
- Save the logic and rerun it as the company evidence changes
Evidence & data
Score breakdownBased on 2 of 6 signals · derived from public data
No clinical pipeline tracked — this score reflects financial & catalyst signals only.
0.9 months
D/E 0.43 · 0% dilution
No tracked pipeline phase
No tracked pipeline candidates
No upcoming catalysts tracked
No insider transactions in the last 180 days
Runway
Financials
Institutional Holdings
Source: SEC Form 13F · as of Mar 2026Institutional holders
3
Total value held
$14K
| Holder | Shares | Value |
|---|---|---|
| xtx topco ltd | 24,041 | $13K |
| rhumbline advisers | 1,878 | $1K |
| morgan stanley | 58 | $33 |
Short Interest
as of May 1, 2026- % of float
- 2.1%
- Days to cover
- 1.4
- Shares short
- 72,973
- Daily short volume (Aug 13, 2026)
- 50.7%
Short percent of float and days-to-cover reflect reported short positioning. Daily short volume is the exchange-reported short share of a single day's trading volume and is noisier. See the most-shorted biotech ranking →
SCNI short interestFrequently asked questions
What is the AI investment thesis for Scinai Immunotherapeutics Ltd.?
Scinai Immunotherapeutics Ltd. is a developmental-stage biopharmaceutical company with two complementary business units: an R&D pipeline focused on inflammation and immunology (including a NanoAb platform and the PC111 program) and a contract development and manufacturing organization (CDMO) subsidiary. The company has no approved products, limited cash, and requires substantial additional financing to continue operations.
Who is the CEO of Scinai Immunotherapeutics Ltd.?
Mr. Amir Reichman M.B.A., M.Sc. is the chief executive officer of Scinai Immunotherapeutics Ltd. (SCNI).
Where is Scinai Immunotherapeutics Ltd. headquartered?
Scinai Immunotherapeutics Ltd. (SCNI) is headquartered in Jerusalem, Israel.
The AI overview and BioSniper Score are neutral, data-derived signals built from public SEC filings, ClinicalTrials.gov and FDA records — not investment advice.